Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CTLA-4 + anti-PD-1 + DC-T cells
- Development stage
- Unknown
- Lead developer
- PLA Army Specialty Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
anti-CTLA-4 + anti-PD-1 + DC-T cells is an investigational combination immunotherapy regimen developed by the Army Medical Center of the PLA for the treatment of advanced solid tumors. This therapeutic approach combines autologous Dendritic Cell-activated T cells (DC-T cells) with dual immune checkpoint inhibition using monoclonal antibodies against Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4). The DC-T cells are generated by co-culturing a patient's T cells with their own dendritic cells to enhance tumor-specific activation. The addition of anti-PD-1 and anti-CTLA-4 antibodies is intended to synergistically prevent T-cell exhaustion and overcome the immunosuppressive mechanisms employed by tumors, thereby promoting a more effective and sustained anti-tumor immune response. This triple combination is currently being evaluated in Phase 1 clinical trials to assess safety and preliminary efficacy in patients with various solid malignancies.
- Other names
- DC-T cells + anti-PD-1 + anti-CTLA-4Dendritic cell-activated T cells + anti-PD-1 + anti-CTLA-4
02
Targets
TCR (T cell antigen receptor complex)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on anti-CTLA-4 + anti-PD-1 + DC-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CTLA-4 + anti-PD-1 + DC-T cells.